Corcept Therapeutics

Krystal Biotech

Arcellx

Avidity Biosciences

Crinetics Pharmaceuticals Inc

Alkermes

Immunovant Inc

Denali Therapeutics

Merus

PTC Therapeutics

ALPS Medical Breakthroughs ETF

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

By ALPS Funds SBIO ON AN ALL-TIME HIGH, TRUMPING JULY’S PEAK While broader equity markets rallied last week, the ALPS Medical Breakthroughs ETF (SBIO) rallied over 10% to surpass its previous all-time high. Biotech stocks continue to gain momentum after President Trump touted Regeneron Pharmaceuticals (REGN; not in SBIO) monoclonal antibody to treat COVID-19, boosting [.

SBIO: Weekly ALPS ETF Spotlight

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Clinical Trials ETF

SPDR S&P Biotech ETF

SPDR S&P Pharmaceuticals ETF

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

By ALPS Funds Last week, the ALPS Medical Breakthroughs ETF (SBIO) posted gains of around 1% and outperformed broader equity markets as well as large-cap biotech indices. Valuations for SBIO’s small-to-mid cap biotech holdings were buoyed by positive M&A (merger & acquisition) sentiment last week and positive drug trial data.

Acquisitions & Postive Drug Data Boost SBIO ETF Again

Virtus LifeSci Biotech Products ETF

Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF  was up nearly 3% at midday, while the Virtus LifeSci Biotech Products ETF  was up 2.7%.

Late-stage biotech ETFs rally Monday on virus treatment hopes

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

The technology sector is often viewed as the epicenter of disruption and innovation, but the healthcare sector isn’t far behind and the ALPS Medical Breakthroughs ETF (SBIO) is one of the preferred ideas for tapping into that trend. With so many traditional pharmaceuticals makers facing looming patent cliffs, innovation matters more today than it ever has [.

When Innovation and Being Nimble Matters, Turn to this Biotech ETF

iShares Nasdaq Biotechnology ETF

The ALPS Medical Breakthroughs ETF (SBIO) is one of many biotechnology ETF garnering attention this year amid the race to defeat the coronavirus, but SBIO also offers investors allure that will extend beyond the pandemic. SBIO is a fresh approach relative to legacy funds in the category.

Betting on Biotech With Utility Beyond Covid-19

The ALPS Medical Breakthroughs ETF (SBIO) is higher by almost 39% over the past 90 days. Importantly, that impressive move is underpinned by strong fundamentals throughout the broader healthcare sector.

Fabulous Fundamentals Brighten Outlook for Healthcare, With This Biotech ETF

Already one of the ETFs at the center of the coronavirus investment thesis, the ALPS Medical Breakthroughs ETF (SBIO) could be poised for more upside as the U.S. grapples with a second wave of the respiratory illness.

Another Round of Coronavirus Cases Puts This Biotech ETF in Focus

On Friday, FTSE Russell, one of the largest providers of benchmarks used by providers of index funds and ETFs, reshuffles its widely followed indexes, including the Russell 1000 and Russell 2000, among others.

A Healthcare ETF Could Benefit From Index Reshuffling

Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish the coronavirus, but there’s more to the story.

Biotech ETFs in the Spotlight, Why They’ll Remain There

In the world of biotechnology stocks and ETFs, investors are pumping up those names with exposure to coronavirus treatments and vaccines.

Biotech ETF Doesn’t Need Coronavirus Vaccines to Soar

Global X Cloud Computing ETF

VanEck Vectors Gold Miners ETF

Intercept Pharma

This trio of uniquely focused exchange-traded funds could make you a lot of money.

Got $1,000? Here Are the Smartest ETFs to Buy and Hold for 5 Years

Sprott Junior Gold Miners ETF

Amplify Junior Silver Miners ETF

The best small-cap ETFs for Q3 2020 are SILJ, SGDJ and SBIO.

Best Performing Small-Cap ETFs for Q3 2020

iShares U.S. Home Construction ETF

Invesco Dynamic Building & Construction ETF

SPDR S&P Homebuilders ETF

Follow Warren Buffett???s latest COVID-19-fighting tips with these ETF strategies.

Follow Warren Buffett With 5 ETF Strategies & Tackle COVID-19

Invesco Solar ETF

These small-cap sector ETFs have put a great show in the past month and are likely to fare better in the post-lockdown period.

Bet on "American Magic" With 4 Solid Small-Cap Sector ETFs

iShares U.S. Healthcare Providers ETF

KraneShares MSCI All China Health Care Index ETF

Invesco S&P SmallCap Health Care ETF

SPDR S&P Health Care Equipment ETF

Health Care Select Sector SPDR Fund

Don't ignore healthcare stocks because 2020 is an election year. Some of these funds are poised for big upside.

7 of the Best Healthcare ETFs to Purchase for 2020

Invesco Dynamic Biotechnology & Genome ETF

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

First-Mover Pandemic Disease Fight ETF On The Way

VanEck Vectors Biotech ETF

iShares Genomics Immunology and Healthcare ETF

iShares U.S. Pharmaceuticals ETF

Invesco DWA Healthcare Momentum ETF

SPDR S&P Health Care Services ETF

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

The ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) was a star performer among healthcare ETFs last year and with small- and mid-cap members of that sector looking poised to renew bullish trends this year, SBIO could again deliver for investors.

Smaller Companies, Big Returns For This Biotech ETF

ALPS Clean Energy ETF

First Trust NASDAQ Clean Edge Green Energy Index Fund

The best Small-Cap ETFs for Q1 2020 are ACES, QCLN, and SBIO.

Best Small-Cap ETFs for Q1 2020

The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.

Best Healthcare ETFs for Q1 2020

Global X Genomics & Biotechnology ETF

iShares U.S. Oil Equipment & Services ETF

Invesco Dynamic Oil & Gas Services ETF

Global X Silver Miners ETF

VanEck Vectors Semiconductor ETF

iShares PHLX Semiconductor ETF

SPDR S&P Semiconductor ETF

While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

4 Sector ETFs That Beat the Market in Q4

ROBO Global Healthcare Technology and Innovation ETF

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

News for ALPS Medical Breakthroughs ETF ETF (SBIO)